Guselkumab, Secukinumab, and Brodalumab rank highly for PASI 75 and PASI 90 in plaque psoriasis
New data ranks different treatments for moderate to severe psoriasis
This systematic review and network meta-analysis of 27 RCTs evaluated IL-23/IL-17 inhibitors for moderate-to-severe plaque psoriasis. Guselk…
Comparing several types of biologics helps patients with plaque psoriasis find which medications rank highest for clearing skin and improvin…
Combination therapies of plant-derived compounds outperform monotherapy for psoriasis vulgaris with specific immunological profiles
Plant compounds combined with standard care improve psoriasis symptoms
This systematic review and network meta-analysis of 84 randomized controlled trials involving 7,544 patients found that combination therapie…
Combining specific plant-derived ingredients with standard treatments may offer better results for people living with psoriasis.
SSGJ-608 achieves 92.7% to 95.1% PASI75 response in moderate-to-severe plaque psoriasis
New injection shows promise for moderate to severe plaque psoriasis
This phase 3 randomized trial in 770 patients with moderate-to-severe plaque psoriasis found that SSGJ-608 (80mg every 2 weeks or 160mg ever…
A new injectable treatment showed high success rates in clearing skin and improving appearance for people with plaque psoriasis.
Icotrokinra 200 mg daily achieves PASI 75 in 73% of patients at Week 16 versus 11% with placebo in moderate-to-severe plaque psoriasis
Oral icotrokinra shows strong results for moderate-to-severe plaque psoriasis
This systematic review and meta-analysis evaluates icotrokinra for moderate-to-severe plaque psoriasis in 1951 patients. The pooled analysis…
A new analysis finds oral icotrokinra helps clear skin faster than placebo in patients with moderate-to-severe plaque psoriasis.
Switching between adalimumab and biosimilar adalimumab-atto shows similar pharmacokinetics in plaque psoriasis
Switching between adalimumab and its biosimilar is safe and similar
This phase 3 RCT in 425 adults with moderate-to-severe plaque psoriasis found that multiple switches between adalimumab RP and biosimilar ad…
A new trial shows that switching between adalimumab and its biosimilar adalimumab-atto is safe and produces similar drug levels in the blood…
FDA Approves Cosentyx (secukinumab) for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older
The FDA has approved a new drug called Cosentyx for treating a serious skin condition
The FDA approved Cosentyx (secukinumab) for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older who are c…
The FDA approved Cosentyx for moderate to severe plaque psoriasis in adults and children 6 and older.
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
The FDA approved a drug called Stelara to treat several inflammatory conditions in adults and children
The FDA approved ustekinumab for adult and pediatric patients 6 years and older with moderate to severe plaque psoriasis and active psoriati…
FDA approved Stelara to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in adults an…
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
The FDA has approved a new drug called Stelara for several inflammatory conditions
The FDA approved ustekinumab for adult and pediatric patients 6 years and older with moderate to severe plaque psoriasis and active psoriati…
The FDA has approved Stelara to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in a…
IL-17A inhibition improves skin lesions and early atherosclerosis markers in psoriasis vulgaris patients
Psoriasis Is Linked to Heart Disease — and One Drug May Help Both
This retrospective cohort and prospective intervention study evaluated IL-17A inhibitors for psoriasis vulgaris and associated cardiovascula…
Psoriasis and heart disease share deep biological roots, and a specific drug may improve both conditions at once.
Network meta-analysis finds biologics superior to placebo for pediatric plaque psoriasis
Biologic treatments help children with moderate to severe psoriasis, analysis finds
A network meta-analysis of randomized controlled trials including 1,016 pediatric psoriasis patients found all biologic therapies significan…
Biologic medicines help children with moderate to severe psoriasis achieve clear skin and better quality of life, analysis finds.
Oral ME3183 shows higher PASI-75 response rates than placebo in moderate to severe plaque psoriasis trial
Could a new pill help clear stubborn psoriasis skin plaques?
A 16-week randomized controlled trial in 132 patients with moderate to severe plaque psoriasis found higher proportions achieving ≥75% PASI …
A new oral pill helped over 60% of patients with moderate to severe psoriasis clear skin plaques significantly better than a placebo in a re…
Phase 2a study of bimekizumab in chronic plaque psoriasis reports pharmacokinetics and PASI change at Week 28
Could a new psoriasis treatment work better by targeting two inflammation sources at once?
A Phase 2a, multicenter, randomized, subject- and investigator-blind study investigated the pharmacokinetics, pharmacodynamics, and safety o…
A new psoriasis drug targets two inflammation sources to see if it works better for thick, scaly skin patches in adults.
Research across Psoriasis
Related studies from across the Psoriasis family.
Obesity is associated with lower PASI90, PASI75, and PASI100 responses in patients with psoriasis
Obesity May Impact How Well Certain Psoriasis Drugs Work
This meta-analysis of 4200 patients found that obesity is associated with lower PASI90 (RR = 0.64), PASI75 (RR = 0.52), and PASI100 (RR = 0.…
New data suggests that patients with obesity may see lower response rates to certain biologic treatments for psoriasis.
Calcium signaling dysregulation drives keratinocyte defects and immune activation in psoriasis
Calcium signaling problems may drive the cycle of psoriasis
This systematic review synthesizes evidence that impaired calcium sensing and SOCE dysfunction in keratinocytes, alongside persistently acti…
New research identifies how faulty calcium signals in skin cells and immune cells could be a key driver of psoriasis symptoms.
Staphylococcal infections may mimic paradoxical psoriasis in patients receiving TNF-alpha inhibitors for systemic conditions
Skin infections can mimic psoriasis during certain medical treatments
This case report series describes 6 patients treated with TNF-alpha antagonists who developed skin lesions initially misdiagnosed as paradox…
Some patients treated for skin conditions may actually have a bacterial infection that looks like a flare-up of their original condition.
Smoking and alcohol linked to higher psoriasis risk in large meta-analysis
Smoking raises psoriasis risk significantly while alcohol shows a smaller effect
This systematic review and meta-analysis of observational studies involving more than 25 million participants found that smoking (RR 1.67) a…
Smoking increases the chance of developing psoriasis, and even quitting keeps that risk higher than never smoking. Alcohol also plays a role…
High-certainty evidence suggests weight-loss interventions improve psoriasis severity and quality of life in adults
Weight loss linked to better psoriasis severity and quality of life
This systematic review and meta-analysis evaluated weight-loss interventions versus usual care or lower-intensity interventions in adults wi…
A review of 1,145 adults with psoriasis found weight-loss interventions improved skin severity and quality of life more than usual care.
Narrative review offers theoretical basis for selecting biologic therapies in psoriasis patients with renal concerns
New Psoriasis Treatments May Protect Kidneys While Fighting Skin Flares
This narrative review examines the use of TNF-alpha, IL-17, and IL-12/23 inhibitors in psoriasis patients with renal concerns. The authors p…
• Some biologics shield kidneys from damage during psoriasis treatment • Helps the 8 million Americans with psoriasis and kidney worries • N…
Targeted therapies for psoriasis and psoriatic arthritis significantly alter lipid profiles across diverse patient populations
Psoriasis drugs change heart risk in surprising ways
A comprehensive meta-analysis of 24,575 patients reveals that targeted therapies for psoriasis and psoriatic arthritis consistently modify l…
Some common psoriasis drugs sharply raise cholesterol while others lower it, forcing doctors to rethink how they protect their patients’ hea…
Systematic review shows regional differences in HS comorbidity prevalence across North America, Europe, and Asia
Regional differences in health risks for hidradenitis suppurativa patients
This systematic review and meta-analysis examines the prevalence of hidradenitis suppurativa-associated comorbidities across North America, …
A meta-analysis reveals how hidradenitis suppurativa patients in North America, Europe, and the Middle East/Asia face different odds for dia…
Imsidolimab shows GPPPGA clearance in generalized pustular psoriasis flare at 4 weeks
A New Drug Clears Severe Skin Flares Fast
This phase 3 randomized controlled trial in 45 patients with a GPP flare found that a single intravenous dose of imsidolimab led to a higher…
A new medicine stops severe skin flares quickly without causing dangerous side effects for most patients
Narrative review discusses ginsenosides for skin conditions including psoriasis and dermatitis with noted evidence gaps
Review of ginsenosides for skin conditions shows weak evidence and low absorption
This narrative review examines the use of ginsenosides for various skin conditions, including psoriasis, dermatitis, photoaging, chronic non…
A review of ginsenosides for skin issues like psoriasis and melanoma found the evidence is insufficient and absorption is low.
Herring roe oil reduces inflammatory biomarkers in mild-to-moderate psoriasis
Herring roe oil may lower inflammation in psoriasis
In a randomized controlled trial post hoc analysis of 64 patients with mild-to-moderate psoriasis, oral herring roe oil supplementation for …
A small trial found that herring roe oil reduced several blood-based inflammation markers in people with mild-to-moderate psoriasis over 26 …
Secukinumab improves skin response in Chinese patients with psoriatic arthritis
Secukinumab linked to skin improvement in Chinese psoriatic arthritis patients
This observational cohort study of 446 Chinese patients with psoriatic arthritis found that treatment with secukinumab for over 12 weeks was…
In Chinese psoriatic arthritis patients, secukinumab treatment was associated with significant skin improvement and better quality of life o…
Questions about Plaque psoriasis
How does bimekizumab compare to placebo for treating moderate to severe chronic plaque psoriasis?
Bimekizumab is significantly more effective than placebo for clearing skin in moderate to severe chronic plaque psoriasis, with Phase 3 trials showing high response rates at week 16.
Full answer →Can Stelara be used to treat plaque psoriasis in pediatric patients 6 years and older?
Yes, Stelara (ustekinumab) is FDA-approved for treating moderate to severe plaque psoriasis in pediatric patients 6 years and older.
Full answer →Is Cosentyx approved for adults with moderate to severe plaque psoriasis?
Yes, Cosentyx (secukinumab) is FDA-approved for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Full answer →Are biologic drugs better than placebo for treating plaque psoriasis in children?
Yes, biologic drugs are significantly more effective than placebo for treating moderate to severe plaque psoriasis in children aged 6 years and older, based on multiple clinical trials and meta-analyses.
Full answer →All Plaque psoriasis Articles
- Guselkumab, Secukinumab, and Brodalumab rank highly for PASI 75 and PASI 90 in plaque psoriasis
- Combination therapies of plant-derived compounds outperform monotherapy for psoriasis vulgaris with specific immunological profiles
- SSGJ-608 achieves 92.7% to 95.1% PASI75 response in moderate-to-severe plaque psoriasis
- Switching between adalimumab and biosimilar adalimumab-atto shows similar pharmacokinetics in plaque psoriasis
- Icotrokinra 200 mg daily achieves PASI 75 in 73% of patients at Week 16 versus 11% with placebo in moderate-to-severe plaque psoriasis
- FDA Approves Cosentyx (secukinumab) for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older
- FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
- FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
- IL-17A inhibition improves skin lesions and early atherosclerosis markers in psoriasis vulgaris patients
- Network meta-analysis finds biologics superior to placebo for pediatric plaque psoriasis
- Oral ME3183 shows higher PASI-75 response rates than placebo in moderate to severe plaque psoriasis trial
- Phase 3 trial compares bimekizumab to placebo and ustekinumab for moderate to severe plaque psoriasis
- Phase 3 trial of bimekizumab versus placebo in 435 adults with moderate to severe plaque psoriasis
- Phase 2a study of bimekizumab in chronic plaque psoriasis reports pharmacokinetics and PASI change at Week 28